Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, with disease progression ranging from slow and indolent to ...
Chronic lymphocytic leukaemia (CLL) is a progressive, malignant disease of the blood-forming ... resistance to therapy in Chronic lymphocytic leukemia (CLL) remain to be explored.
Chronic lymphocytic leukemia (CLL) is usually a slow-growing blood cancer. Most people with CLL don’t notice any problems in the early stages of the disease. “In fact, we can do what we call ...
An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...
Hope is crucial for those of us with chronic lymphocytic leukemia, or any cancer, helping us navigate the disease's ...
A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...
TBI remained significantly associated with reduced adjusted risks of grade 3 to 4 aGVHD and moderate-severe cGVHD.
Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while ...
Her medical history was notable for chronic lymphocytic leukemia (CLL), which had been under surveillance for 15 years; hypertension; dyslipidemia; and chronic kidney disease with an estimated ...
Venetoclax, a selective Bcl-2 inhibitor, has proven effective in chronic lymphocytic leukemia (CLL), but genetic mutations or ...
would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia (CLL) is unknown. In this phase 3, open-label trial, we included ...